title: Allotransplanted neurons used to repair peripheral nerve injury do not elicit overt immunogenicity.
abstract: A major problem hindering the development of autograft alternatives for repairing peripheral nerve injuries is immunogenicity. We have previously shown successful regeneration in transected rat sciatic nerves using conduits filled with allogeneic dorsal root ganglion (DRG) cells without any immunosuppression. In this study, we re-examined the immunogenicity of our DRG neuron implanted conduits as a potential strategy to overcome transplant rejection. A biodegradable NeuraGen® tube was infused with pure DRG neurons or Schwann cells cultured from a rat strain differing from the host rats and used to repair 8 mm gaps in the sciatic nerve. We observed enhanced regeneration with allogeneic cells compared to empty conduits 16 weeks post-surgery, but morphological analyses suggest recovery comparable to the healthy nerves was not achieved. The degree of regeneration was indistinguishable between DRG and Schwann cell allografts although immunogenicity assessments revealed substantially increased presence of Interferon gamma (IFN-γ) in Schwann cell allografts compared to the DRG allografts by two weeks post-surgery. Macrophage infiltration of the regenerated nerve graft in the DRG group 16 weeks post-surgery was below the level of the empty conduit (0.56 fold change from NG; p<0.05) while the Schwann cell group revealed significantly higher counts (1.29 fold change from NG; p<0.001). Major histocompatibility complex I (MHC I) molecules were present in significantly increased levels in the DRG and Schwann cell allograft groups compared to the hollow NG conduit and the Sham healthy nerve. Our results confirmed previous studies that have reported Schwann cells as being immunogenic, likely due to MHC I expression. Nerve gap injuries are difficult to repair; our data suggest that DRG neurons are superior medium to implant inside conduit tubes due to reduced immunogenicity and represent a potential treatment strategy that could be preferable to the current gold standard of autologous nerve transplant.
authors.affiliation: Department of Neurosurgery, University of Rochester, Rochester, New York, United States of America.
authors.forename: Weimin
authors.initials: W
authors.lastname: Liu
authors.forename: Yi
authors.initials: Y
authors.lastname: Ren
authors.forename: Adam
authors.initials: A
authors.lastname: Bossert
authors.forename: Xiaowei
authors.initials: X
authors.lastname: Wang
authors.forename: Samantha
authors.initials: S
authors.lastname: Dayawansa
authors.forename: Jing
authors.initials: J
authors.lastname: Tong
authors.forename: Xiaoshen
authors.initials: X
authors.lastname: He
authors.forename: Douglas H
authors.initials: DH
authors.lastname: Smith
authors.forename: Harris A
authors.initials: HA
authors.lastname: Gelbard
authors.forename: Jason H
authors.initials: JH
authors.lastname: Huang
mesh_terms: D000818:Animals; D017690:Cell Transplantation / Q000379:methods*; D005727:Ganglia, Spinal; D055261:Immunogenetic Phenomena; D009416:Nerve Regeneration; D009474:Neurons / Q000637:transplantation*; D059348:Peripheral Nerve Injuries / Q000628:therapy*; D051381:Rats; D012583:Schwann Cells; D012584:Sciatic Nerve; D014184:Transplantation, Homologous; D014945:Wound Healing